Skip to main content
KRYS logo

Krystal Biotech, Inc. (KRYS) Stock: Price, Forecast & Analyst Target

Krystal Biotech, Inc. (KRYS) — MoonshotScore 96/100 (Exceptional band), calculated Nov 18, 2026. Price $315.82 (+0.15%), as of the Nov 19, 2026 trading session; market cap $9.36B. Expected results Feb 16, 2027.

Educational signal · not a buy or sell recommendation · How to read this

Market value / cash and short-term investments: 10.26× (cash as of Sep 30, 2026) · expected results Feb 16, 2027

$315.82 +$0.48 (+0.15%) Market Cap $9.36B

Krystal Biotech, Inc. · KRYS · NASDAQ · Healthcare · Biotechnology

Research dated 2026-09-13 (results through the quarter ended Jun 2026; the quarter ended Sep 2026 not covered): Krystal Biotech develops redosable gene therapies for severe orphan diseases, with B-VEC at the front of a broader dermatology and rare-disease pipeline. Reported economics no longer resemble a pre-revenue biotechnology developer: sales, profit, and operating cash flow are established, while liquidity continues to build. The case now rests on whether that revenue base can keep expanding without the expense base outrunning demand.

Price as of Nov 19, 2026

Key Statistics

96 of 100

MoonshotScore v2 · Krystal Biotech (KRYS)

Exceptional
Business Quality Elite (95)
Financial Safety Fortress (96)
Valuation Full (40)
Growth Durability Compounding (91)
Momentum Rising (78)
Why this rating? Method, drivers & history

Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.

  • Business Quality — Is this a genuinely good business?
  • Financial Safety — Could this blow up on me?
  • Valuation — Am I paying a fair price?
  • Growth Durability — Is the growth real and likely to last?
  • Momentum — Is the market already moving on this?
The ten-second read ·

Elite quality, a fortress balance sheet and elite growth, but a full valuation; the market is already moving on it. Business Quality: Elite; Financial Safety: Fortress; Valuation: Full; Growth Durability: Compounding; Momentum: Rising.

  • EPS beat 7 of the last 8 reports
  • Altman Z 36.92 · Piotroski F 4
  • ROE 17.5% · ROA 10.1% · current ratio 7.89

Helping: business quality, balance-sheet strength, durable growth, positive momentum

What has the MoonshotScore done over time?

MoonshotScore snapshots recorded for KRYS (57 recorded, newest six shown)
RecordedScoreBand
97Exceptional
97Exceptional
89Exceptional
89Exceptional
96Exceptional
96Exceptional

Daily score refresh is delayed. This is the last recorded calculation.

Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.

Computed · How the MoonshotScore is computed →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$315.82
Change on the day+0.15%
52-week range$202.99–$382.54
Market capitalisation$9.36B—
Price / earnings (trailing)38.98
Shares traded on the day295.9K
Beta (volatility vs the S&P 500)0.5

Why Krystal Biotech scores 96

Dr. Mira Sol, the Stock Expert AI TV data character
Financial Safety carries the score; Valuation is what holds it back.
Dr. Mira Sol · Data scientist, Stock Expert AI TV (fictional AI character)
96Exceptional
  • Business Quality95
  • Financial Safety96
  • Valuation40
  • Growth Durability91
  • Momentum78

Share price, last 12 months +51.7%

$201.21 $305.23

What the price assumes

12.2% a year of free-cash-flow growth for ten years is what a $9.05B market value ( snapshot) asks for.

  • Price implies, next ten years12.2%
  • Analysts' revenue path, 2026–203040.3%

The growth the price implies sits inside what the business has recently delivered, so the valuation leans on that record continuing.

Reverse discounted cash flow: 10% discount rate, 3% growth after year ten, starting from trailing twelve months free cash flow of $310.08M. Inputs: FMP statements, estimates and quote.

How the stock reacts to earnings

EPS beat in 10 of the last 12 reports (2024–2026); the stock still fell the next session after 5 of those beats. Average first-session move: 11.0% either way.

  1. +52.8%Feb ’24
  2. +0.4%May ’24
  3. -6.9%Aug ’24
  4. -1.1%Nov ’24
  5. +16.5%Feb ’25
  6. -15.7%May ’25
  7. -12.5%Aug ’25
  8. +2.9%Nov ’25
  9. +2.5%Feb ’26
  10. +7.0%May ’26
  11. -4.8%Aug ’26
  12. -8.2%Nov ’26
Next-session move EPS beat (10) EPS miss (2)
Every report, with revenue and five-session moves
Moves run from the close before the report to the first and fifth closes after it.
ReportEPSRevenueNext session5 sessions
BeatBeat-8.2%-8.8%
BeatMiss-4.8%-2.8%
BeatBeat+7.0%+17.6%
BeatBeat+2.5%-3.5%
BeatMiss+2.9%+1.0%
BeatIn line-12.5%-12.4%
MissMiss-15.7%-17.1%
BeatIn line+16.5%+12.6%
BeatMiss-1.1%+11.0%
BeatBeat-6.9%-3.9%
MissMiss+0.4%-3.9%
BeatBeat+52.8%+43.7%

Misses cost real money here: the average first-session move after a miss was -7.6%.

What management is saying differently

Management's own words on the Q3 FY2026 call () against Q2 FY2026 (). Analysts' questions are left out.

  • New this call: “additional patients”, “academic sites” — none of them came up in Q2 FY2026.
  • Gone quiet: “patient-reported outcome”, “before year-end”, “global filing”, “hailey-hailey disease” — regular themes last call, absent this time.
  • Tone: Cautious words such as “may”, “could” and “headwind” fell from 2.9 to 0.5 per 1,000 words, and confident words such as “record” and “strong” fell from 3.5 to 1.7.

Management sounded more assured than a quarter earlier — fewer hedging words, more of the confident kind.

Our track record on this stock

Since the score went from 99 to 96 while the share price moved -7.6% through .

MoonshotScore (0–100, band floors 45 · 65 · 80) Share price, scaled to its own range

The score has stayed in the Exceptional band across the stretch we have recorded; we grade each band change three months after it happens.

The crowd against our signals

  • Analysts: 100% of 18 rate it a buy; the average target sits +32.5% from the price of $315.82.
  • Last 90 days: 5 rating actions, every one a reaffirmation.
  • Our signals: Exceptional band; strongest pillar Financial Safety (96), weakest Valuation (40).

Here we and the crowd agree. Where we differ is on price: our Valuation reading is more cautious than the analysts' targets.

Price & events

Weekly closing price with reported quarters marked Weekly closing price from Oct 17, 2025 to Nov 19, 2026: low $186, high $375, latest $316. 4 reported quarters marked, 4 above and 0 below the recorded estimate. 1 other dated event marked. $375 $186 high $375 Feb 17, 2026 · Earnings results · reported above the recorded estimate · close $2621May 4, 2026 · Earnings results · reported above the recorded estimate · close $2662Aug 3, 2026 · Earnings results · reported above the recorded estimate · close $3413Nov 2, 2026 · Earnings call · management outlook · no recorded estimate to compare · close $3324Nov 2, 2026 · Earnings results · reported above the recorded estimate · close $3325 Oct 17, 2025 Nov 19, 2026 · $316 $190Oct 17, 2025$198Oct 31, 2025$206Nov 14, 2025$218Nov 28, 2025$245Dec 12, 2025$252Dec 26, 2025$261Jan 9, 2026$282Jan 23, 2026$273Feb 6, 2026$262Feb 20, 2026$254Mar 6, 2026$252Mar 20, 2026$261Apr 2, 2026$274Apr 17, 2026$266May 1, 2026$306May 15, 2026$309May 29, 2026$318Jun 12, 2026$372Jun 26, 2026$366Jul 10, 2026$335Jul 24, 2026$326Aug 7, 2026$347Aug 21, 2026$358Sep 4, 2026$337Sep 18, 2026$322Oct 2, 2026$317Oct 16, 2026$332Oct 30, 2026$305Nov 13, 2026

Triangles mark reported quarters on the line: pointing up is above the recorded estimate, down is below, a diamond means no estimate on file or a dated event that is not a results report. Numbers key to the dated list. Point at or tab to any week for its close.

Events behind the price

  • · Earnings results · above the recorded estimate
  • · Earnings results · above the recorded estimate
  • · Earnings results · above the recorded estimate
  • · Earnings call · management outlook
  • · Earnings results · above the recorded estimate

Results dates follow the earnings feed; call dates follow the transcript provider. Nearby dates do not establish that an event caused a price move.

Upcoming events

As of

  1. Next results dueProvider estimate

Management outlook

  • Based on this enrollment timeline, we now anticipate interim study results in the first half of 27.

    Suma Krishnan · Statement from

  • With continued investment and expansion of our trial network, we now expect to complete the enrollment and report top-line results in 2027.

    Suma Krishnan · Statement from

How to read these dates

A statement's date is the earnings call where it was made, not a deadline. Management expectations and estimated dates can change.

What to watch next

Other perspectives

Council score for Krystal Biotech (KRYS): perspectives

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

5-Factor Breakdown

Business Quality Strong
Financial Safety Strong
Valuation Neutral
Growth Durability Strong
Momentum Moderate

Legends Council

5 lenses, 5 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Dalio-style lens (simulated) Ray Dalio Favorable read
Griffin-style lens (simulated) Ken Griffin Favorable read
Englander-style lens (simulated) Izzy Englander Neutral read
Klarman-style lens (simulated) Seth Klarman Neutral read
Moon AI lens (model) Favorable read

Read on: Nov 20, 2026

Munger's Mindset

Balance Sheet & Valuation

Financial Health Strong
Margin of Safety Fairly Valued
Profit Margin Strong
Revenue Growth Strong
Debt/Equity Strong
ROE Moderate
Gross Margin Strong

Read on: Nov 19, 2026

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

The Munger lens reads the current price as fairly valued against its own estimate of value.

Readings on this page are from Nov 20, 2026, except a card that shows its own read date.

1 · What is it?

What is Krystal Biotech (KRYS), and what does it report?

Short answer · as of

Krystal is a gene-therapy developer built around treatments that can be administered repeatedly rather than a diversified drug manufacturer.

Its programs span severe inherited skin disorders, cystic fibrosis, and aesthetic dermatology, with B-VEC identified as the most advanced candidate. The economic task is to translate those programs into patient treatment; clinical progress by itself is not revenue.

2 · Latest results

What do the latest results show for Krystal Biotech (KRYS)?

Revenue advanced again in the latest reported period, while gross profit kept pace. Research spending and selling, general, and administrative expense each eased from the preceding period, allowing operating profit to rise even as net profit declined modestly. The immediate mechanism was operating leverage within the reported cost base, not a reduction in gross profitability.

Where is operating spending going?

Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.

Latest quarter · revenue
$127.34M Sep 30, 2026
Latest quarter · R&D
$14.89M Sep 30, 2026
Latest quarter · SG&A
$33.75M Sep 30, 2026
Latest quarter · FMP standardized operating result
$71.14M Sep 30, 2026
Period endRevenueR&DSG&AFMP standardized operating result
Sep 30, 2026$127.34M$14.89M$33.75M$71.14M
Jun 30, 2026$119.22M$14.52M$39.85M$58.42M
Mar 31, 2026$116.36M$15.33M$41.01M$53.69M
Dec 31, 2025$107.11M$16.20M$41.28M$44.44M
How to read these figures

Amounts are in US dollars. The operating result is Financial Modeling Prep’s standardized figure, so it can differ from the operating line in the company’s filing. It is not net income or cash flow.

Did results meet expectations?

Reported earnings and revenue alongside the estimates recorded by the provider.

Latest report · revenue
$127.34M Nov 2, 2026
Latest report · revenue estimate
$125.77M Nov 2, 2026
Latest report · revenue vs estimate
Above estimate Nov 2, 2026
Latest report · EPS vs estimate
Above estimate Nov 2, 2026
Report dateRevenue · reportedRevenue · estimateEPS · reportedEPS · estimate
Nov 2, 2026$127.34M$125.77M$2.0500$1.7900
Aug 3, 2026$119.22M$120.93M$1.7900$1.7000
May 4, 2026$116.36M$112.11M$1.8300$1.4500
Feb 17, 2026$107.11M$105.35M$1.7000$1.6200
How to read these figures

Dates are when results were reported, not quarter ends. Amounts are in US dollars; EPS is per share. The source does not say whether EPS is basic, diluted or adjusted, so it can differ from the EPS in the income statement.

Quarterly income statement — 4 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Sep 2026$127M$63M$2.05 (diluted)
Jun 2026$119M$55M$1.79 (diluted)
Mar 2026$116M$56M$1.83 (diluted)
Dec 2025$107M$51M$1.70 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for Krystal Biotech (KRYS)?

Short answer

Cash and short-term investments were $911.85M at the Sep 30, 2026 balance-sheet date. Operating cash flow was $91.25M for the quarter ended Sep 30, 2026, meaning operations generated cash. These figures do not establish a cash runway.

Krystal carries substantial cash and short-term investments, an additional pool of long-term investments, and little debt. Positive operating cash flow throughout the displayed run, paired with comparatively modest capital spending, has allowed liquid resources to rise while the company continues funding research and commercial overhead.

How much cash does the business generate or use?

Quarterly operating cash flow shows cash generated or used by operations.

Latest quarter · operating cash flow
$91.25M Sep 30, 2026
Previous quarter · operating cash flow
$74.79M Jun 30, 2026
Period endOperating cash flowCapital expenditure (reported)
Sep 30, 2026$91.25M−$1.00M
Jun 30, 2026$74.79M−$3.56M
Mar 31, 2026$80.38M−$7.15M
Dec 31, 2025$77.51M−$2.14M
How to read these figures

Amounts are in US dollars. Negative operating cash flow means the business used cash. Capital spending is shown as reported; we do not combine it into a free-cash-flow or runway estimate. The bars share one scale.

4 · What to check next?

What should you watch next at Krystal Biotech (KRYS)?

Short answer · as of

The next earnings report is expected on Feb 16, 2027. The number it tests is the $7.67 EPS analysts carry for it.

Krystal’s scheduled earnings release puts revenue continuity, operating leverage, and cash conversion in focus. Useful confirmation would be another advance in revenue accompanied by resilient gross profit, controlled operating expenses, positive operating cash flow, and further preservation of liquidity.

What management is planning

Management's statements are quoted under Upcoming events

5 · Peer comparison

How does Krystal Biotech compare with its peers?

Short answer

Krystal Biotech's score ranks 3rd of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.

Development-stage rare-disease companies commonly depend on external capital while awaiting commercial validation; Krystal already reports recurring revenue, operating profit, net income, and positive operating cash flow. Yet its strategic identity remains that of a focused redosable gene-therapy platform rather than a diversified commercial biopharma business. That combination makes present earnings quality and candidate progression equally relevant comparisons.

Peer set — price, market value and MoonshotScore
CompanyPriceMarket valueScore
Kiniksa Pharmaceuticals, Ltd. (KNSA) Same industry, near in market value$93.53 Nov 19, 2026$7.35B98 5-pillar Nov 18, 2026
Exelixis, Inc. (EXEL) Same industry, near in market value$65.83 Nov 19, 2026$16.1B98 5-pillar Nov 18, 2026
Krystal Biotech (KRYS) — this page$315.82$9.36B96
Halozyme Therapeutics, Inc. (HALO) Same industry, near in market value$93.04 Nov 19, 2026$10.6B95 5-pillar Nov 18, 2026
Neurocrine Biosciences, Inc. (NBIX) Same industry, near in market value$162.86 Nov 18, 2026$16.5B95 5-pillar Nov 18, 2026
Bio-Techne Corporation (TECH) Same industry, near in market value$72.70 Nov 19, 2026$11.4B92 5-pillar Nov 18, 2026
Corcept Therapeutics Incorporated (CORT) Same industry, near in market value$67.79 Nov 18, 2026$7.42B91 5-pillar Nov 18, 2026
TG Therapeutics, Inc. (TGTX) Named competitor$64.88 Nov 19, 2026$9.81B90 5-pillar Nov 18, 2026
Protagonist Therapeutics, Inc. (PTGX) Named competitor$127.16 Nov 18, 2026$8.30B88 5-pillar Nov 18, 2026
Caris Life Sciences, Inc. (CAI) Same industry, near in market value$19.50 Nov 18, 2026$5.59B83 5-pillar Nov 18, 2026
Ligand Pharmaceuticals Incorporated (LGND) Same industry, near in market value$298.71 Nov 18, 2026$5.98B71 5-pillar Nov 18, 2026
Oruka Therapeutics, Inc. (ORKA) Same industry, near in market value$97.57 Nov 19, 2026$6.62B67 5-pillar Nov 18, 2026
Belite Bio, Inc. (BLTE) Same industry, near in market value$156.23 Nov 18, 2026$6.35B64 5-pillar Nov 18, 2026

Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.

Screen more Healthcare stocks

The records behind this page

Analyst targets & estimates

What analysts have on file

Price target, low to high
$361.00 – $474.00
Consensus target
$418.40
Median target
$416.00
Revenue estimate
$497.50M
EPS estimate
$7.67

Consensus record · Captured .

Measured against a quoted price of $315.82 (as of Nov 19, 2026).

Insider activity

Form 4 records via FMP · Of the newest 100 records, those within the last 180 days, newest dated Nov 12, 2026

Transactions
74
Identified insiders
9
Purchases
0
Sales
58
Other transactions
16

Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.

Who holds the shares?

Institutional ownership reported through 13F filings.

Reporting holders
465 Period end Sep 30, 2026
Previous quarter · holders
443 Prior to period end Sep 30, 2026
Holders in provider snapshotShares
Fmr LLC4,439,770
Blackrock, INC.3,590,630
Avoro Capital Advisors LLC2,888,888
State Street Corp1,420,127
Vanguard Portfolio Management LLC1,286,854

Tracked investors

Which of the 16 named investors we follow held KRYS in their latest 13F filing, and what they did against the filing before it.

InvestorManager13F quarterPortfolio weightValueLast quarter
Bridgewater AssociatesFounded by Ray DalioQ3 20260.14%$33.23MAdded +83.4% shares

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Holder snapshot as of Sep 30, 2026. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

What has been published about Krystal Biotech (KRYS)?

Read these with our analysis →

Krystal Biotech Healthcare Stock: Key Questions Answered

The last 2 questions are answered from this page's own dated data, not from the research.

What is B-VEC’s role in Krystal Biotech’s business?

B-VEC is Krystal’s most advanced therapeutic candidate and the clearest program-level test of its redosable gene-therapy approach. The remaining pipeline extends that platform across inherited skin disease, cystic fibrosis, and aesthetic dermatology.

Is Krystal Biotech still a clinical-stage biotechnology company?

Clinical development remains central to Krystal’s identity, but its financial profile is no longer pre-revenue. The company now reports substantial revenue, operating profit, net income, and positive operating cash flow alongside continued research spending.

Can Krystal fund its redosable gene-therapy pipeline internally?

Current operations are generating cash while liquid resources and investments comfortably exceed debt. That combination gives Krystal room to fund research without relying on balance-sheet depletion at the recent operating pace.

What do recent KRYS insider transactions show?

Recent recorded activity was dominated by sales and other transfers, with no purchases recorded. The pattern offers no affirmative buying signal, although the transactions alone do not establish why insiders sold.

What is the KRYS stock price today?

The last price recorded for Krystal Biotech, Inc. (KRYS), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What is the KRYS price target?

The analyst consensus price target for Krystal Biotech, Inc. (KRYS), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.

Research written by Codex (gpt-5.6-sol) on 2026-09-13. AI-authored analysis; source dates are listed under Sources. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 80 figures on this page — 2 from SEC filings and earnings calls, 68 from Financial Modeling Prep (FMP), 6 with no recorded source, 3 computed by us, formula shown in the register and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections

Sources (as of 2026-09-13), by section of the research

  • Summary at the top of the page: Legal name; Business description; Annual revenue and net result (USD millions); Quarterly income statement (USD thousands); Operating cash flow by quarter (USD millions); Cash and short-term investments over time (USD millions)
  • 1. What is Krystal Biotech (KRYS), and what does it report?: Business description; Sector / industry (provider taxonomy)
  • 2. What do the latest results show for Krystal Biotech (KRYS)?: Quarterly income statement (USD thousands)
  • 3. What are the financial strengths and risks for Krystal Biotech (KRYS)?: Cash, investments and debt; Cash and investment components; Cash and short-term investments over time (USD millions); Operating cash flow by quarter (USD millions)
  • 4. What should you watch next at Krystal Biotech (KRYS)?: Next earnings report; Quarterly income statement (USD thousands); Operating cash flow by quarter (USD millions); Cash and short-term investments over time (USD millions)
  • 5. How does Krystal Biotech compare with its peers?: Business description; Annual revenue and net result (USD millions); Quarterly income statement (USD thousands); Operating cash flow by quarter (USD millions)
  • FAQ: What is B-VEC’s role in Krystal Biotech’s business?: Business description
  • FAQ: Is Krystal Biotech still a clinical-stage biotechnology company?: Business description; Annual revenue and net result (USD millions); Quarterly income statement (USD thousands); Operating cash flow by quarter (USD millions)
  • FAQ: Can Krystal fund its redosable gene-therapy pipeline internally?: Cash, investments and debt; Cash and investment components; Cash and short-term investments over time (USD millions); Operating cash flow by quarter (USD millions)
  • FAQ: What do recent KRYS insider transactions show?: Insider transactions, last 180 days; What the sources do not tell us
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.

ETFs that hold KRYS

Funds in our ETF coverage that list KRYS among the top 10 holdings on their fund page, largest weight first. Each weight is the fund's reported holding weight as of the date in its row.

ETFWeightHoldings as of
iShares Russell 2000 ETF (IWM)0.30%